|
 The British group said on Thursday up it would receive up to $230
million in sales and other related milestones over the lifetime of
the contract, with Gruenenthal also paying royalties on sales.
In April, Ironwood Pharmaceuticals bought U.S. marketing rights to
the newly approved drug for up to $265 million.
AstraZeneca has a strategy of selling certain rights to non-core
medicines as it invests in new drugs. But the disposal of Zurampic
has led some analysts to question the success of its past
acquisitions, since AstraZeneca only bought the drug's original
developer Ardea Biosciences in 2012 for $1.26 billion.
(Reporting by Ben Hirschler. Editing by Jane Merriman)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
